Compare Hims and Hers Health Inc (HIMS) vs Mercadolibre Inc (MELI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Mercadolibre Inc — how do they compare? Hims and Hers Health Inc trades at $29.29 (market cap $6.55B), while Mercadolibre Inc trades at $1,873.35 (market cap $94.13B). The key difference: Mercadolibre Inc is far larger — about 14.4× Hims and Hers Health Inc's market cap, and Mercadolibre Inc is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Mercadolibre Inc for 117 Days on average.
| HIMS | MELI | |
|---|---|---|
Market Cap | $6.55B | $94.13B |
Volume | 14,842,814 | 273,781 |
Sector | Health | Consumer Cyclical |
52-Week High | $62.76 | $2.36K |
52-Week Low | $14.52 | $1.55K |
Typical Hold Time | 21 Days | 117 Days |
Enterprise Value | $7.25B | $101.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.
The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.
MercadoLibre (MELI) trades at $1,868.01, down 0.25% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust revenue growth, reaching $28.89 billion in 2025, though net income margin compressed to 6.91%. Recent news highlights expansion in Brazil's delivery and pharmacy segments, while analyst consensus remains strongly bullish with a $2,170 price target.
MELI's integrated e-commerce and fintech ecosystem in Latin America presents significant growth potential, supported by expanding credit portfolios and advertising revenue. Key risks include macroeconomic pressures in Argentina and margin compression from increased investment. With 73% analyst buy ratings and institutional accumulation, the stock offers growth exposure but requires monitoring of profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
